Oncoprint of co-occurring mutations observed in WT1-mutated adult patients with de novo AML. Patients in whom single-cell DNA sequencing was performed are marked in purple. Patients with truncating WT1 mutations are shown in blue and patients with nontruncating mutations are shown in green. Patients carrying FLT3-ITD are marked in red, those with NRAS mutations magenta, those with FLT3-TKD orange, and those with mutations in the remaining genes in black. White denotes wild-type genes or the absence of FLT3-ITD or FLT3-TKD; light gray indicates unknown mutational gene status.